Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methotrexate: first-line or second-line immunomodulator?

Alan G Fraser1

  • 1University of Auckland, New Zealand. a.fraser@auckland.ac.nz

European Journal of Gastroenterology & Hepatology
|March 1, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Artificial stupidity or logimorphism? How misuse of language warps our thinking about 'artificial intelligence'.

European heart journal. Digital health·2026
Same author

Clinical Evidence and FDA Recalls of Artificial Intelligence-Enabled Medical Devices.

JAMA network open·2026
Same author

Myocardial relaxation, left ventricular filling, and exercise capacity in older subjects with dyspnea.

American journal of physiology. Heart and circulatory physiology·2026
Same author

Physician-centered monitoring of AI-enabled medical devices.

The American journal of medicine·2026
Same author

Clinical significance of field safety notices concerning implantable pacemakers and defibrillators.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same author

Reduce bureaucracy in clinical trials now.

Nature medicine·2026
Same journal

Comment on 'Associations between 12 insulin resistance surrogates with metabolic dysfunction-associated steatotic liver disease risk and all-cause mortality: data from the National Health and Nutrition Examination Survey III (1988-1994)'.

European journal of gastroenterology & hepatology·2026
Same journal

Alarm symptoms at diagnosis of coeliac disease and long-term outcomes.

European journal of gastroenterology & hepatology·2026
Same journal

Artificial intelligence-integrated nanotherapeutics for rare Peutz-Jeghers syndrome hamartoma-induced obstructions: latest clearance strategies.

European journal of gastroenterology & hepatology·2026
Same journal

'Presence of alarm symptoms at coeliac disease diagnosis is not associated with poorer long-term treatment outcomes' [Letter].

European journal of gastroenterology & hepatology·2026
Same journal

Atrial fibrillation in patients with alcohol-associated hepatitis leads to increased mortality.

European journal of gastroenterology & hepatology·2026
Same journal

Association between albumin-bilirubin score, model for end-stage liver disease score, platelet-albumin-bilirubin score, and acute-on-chronic liver failure complications: a cross-sectional study in a Chinese population.

European journal of gastroenterology & hepatology·2026
See all related articles

Methotrexate effectively induces remission in Crohn's disease. It is recommended for patients unresponsive or intolerant to azathioprine or 6-mercaptopurine, with comparisons to rheumatoid arthritis treatment.

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Immunology

Background:

  • Crohn's disease management often involves immunomodulators.
  • Methotrexate is an established treatment for various inflammatory conditions.

Purpose of the Study:

  • To review methotrexate's role in Crohn's disease treatment.
  • To compare methotrexate with thiopurines and discuss its use in ulcerative colitis.

Main Methods:

  • Literature review of mechanisms of action, pharmacokinetics, and clinical trials.
  • Comparative efficacy analysis against thiopurines.
  • Discussion of toxicity and use in rheumatoid arthritis.

Main Results:

  • Methotrexate is effective for inducing remission and preventing relapse in Crohn's disease.

Related Experiment Videos

  • It is a viable option for patients refractory or intolerant to azathioprine/6-mercaptopurine.

    • Conclusions:

    • Methotrexate is a valuable therapeutic option for refractory Crohn's disease.
    • Further research may clarify its role in ulcerative colitis and long-term safety profiles.